

Press release

1 September, 2021

Curasight A/S strengthens its institutional investor base

Copenhagen, Denmark, 1 September 2021 – Curasight A/S (“Curasight” or the “Company”) has strengthened its institutional investor base as part of the company's future strategy. Arbejdernes Landsbank has today acquired 200,000 warrants from the Swedish investment company Eastbridge, which is already a strategic investor in Curasight.

The transaction between Arbejdernes Landsbank and Eastbridge takes place as a so-called block trade, which means that the actual transfer of 200,000 warrants does not affect the price in the market and no warrants holders are diluted or otherwise impaired. Arbejdernes Landsbank is intended to exercise all 200,000 warrants when the exercise window opens.

Head of Treasury, Carsten Hammershøj, from Arbejdernes Landsbank says that *“we find Curasight a very interesting company with great potential in cancer diagnosis and treatment. We are excited that there was an opportunity to come on board as an investor and become part of the forward journey.”*

Eastbridge says in a statement – *“we are welcoming Arbejdernes Landsbank as a long-term shareholder, and we know about their commitment from other investments we both are involved in. Therefore, we offered a part of our warrants to Arbejdernes Landsbank as it will further strengthen the investor base going forward. Eastbridge remains a long-term shareholder in Curasight, and we still keep a majority of our holding after the block transaction.”*

In conclusion, says CEO Ulrich Krasilnikoff - *“we are truly pleased with the transaction and to welcome Arbejdernes Landsbank on board. They are a recognized and respected long-term investor. For us, this is a first step in terms of strengthening our investor base and getting more Nordic and international investors on board in our effort to unfold the full potential in Curasight.”*

The warrants that have been traded today in the block trade are part of the total of 2,835,000 warrants issued in connection with the IPO in October 2020. The exercise period for the warrants is from the 16th of September 2021 until the 7th of October 2021. Exercise price: One (1) warrant gives the right to subscribe for one (1) new share at DKK 17.20 in Curasight. Issue volume: If all warrants are exercised during this period, the company will receive an additional approximately DKK 48.2 million before issue costs.

There will be more ongoing information about the exercise period of the warrants in the coming weeks.



PROVIDING ANSWERS FOR CANCER PATIENTS

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.